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Risk Factors for Antimicrobial Resistance Among the  
Escherichia coli Strains Isolated from Korean Patients with Acute 
Uncomplicated Cystitis: A Prospective and Nationwide Study
We investigated the risk factors for resistance to ciprofloxacin, cefazolin, ampicillin and co-
trimoxazole in Escherichia coli isolates from urine of Korean female patients with acute 
uncomplicated cystitis (AUC). A total of 225 patients and their E. coli isolates were 
prospectively and nationwidely enrolled between May and October, 2006. All the 
antimicrobials did not show any differences according to the age group. A higher rate of 
ciprofloxacin resistance was observed in the south (OR: 3.04, 95% CI: 1.19-7.80 for 
Chungcheong-do & Jeolla-do; OR: 3.04, 95% CI: 1.22-7.58 for Gyeongsang-do) compared 
to Gyeonggi-do. Two recurrences of AUC in the past year was an important risk factor for 
antimicrobial resistance (ciprofloxacin; OR: 6.71, 95% CI: 1.86-24.11 and cefazolin; OR: 5.72, 
95% CI: 1.20-27.25). However, the resistance to co-trimoxazole and ampicillin was not 
associated with any of the risk factors. This study also revealed the pattern of multi-drugs 
resistance in ciprofloxacin resistant E. coli strains. In conclusion, for Korean patients with 
two more recurrences of AUC in the past year, it is strongly recommended to perform an 
antimicrobial sensitivity test with a urine sample before empirical treatment.
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INTRODUCTION
Acute uncomplicated cystitis (AUC) is the most commonly en-
countered bacterial infections in healthy women. The current 
management of AUC is usually a short course of empirical treat-
ment with co-trimoxazole or fluoroquinolones in areas where 
resistance to co-trimoxazole is prevalent. This antibiotics are 
tried without performing a urine culture or susceptibility test-
ing to guide therapy (1). However, there has been a significant 
increase in resistance of Escherichia coli strains to antimicrobials 
worldwide (2-8). The adverse consequences of using antimi-
crobials to treat a strain that is resistant to these antimicrobials 
may be a delay in resolution of the infection and the consequent-
ly increased social costs such as days lost from work or school 
for some women (9). 
  Fluoroquinolone or co-trimoxazole resistance by E. coli has 
been detected at a high rate in the Asia-Pacific region in recent 
years (2-5). Moreover, some countries in Asia do not currently 
consider fluoroquinolone as a first line treatment for recurrent 
cystitis (3, 6). Consequently, new therapeutic options in the set-
ting of high resistance against fluroquinolone need to be found. 
Therefore, the clinicians in local areas, before deciding on the 
best empirical regimen to use for AUC in this era of increased 
drug resistance, they must know the patterns of drug resistance 
and assess the risk factors for drug resistance in their local area. 
However, there are not many studies on the drug resistance pat-
tern of AUC in Korea (2, 3). The designs of the previously report-
ed papers in Korea were retrospective studies and they were  
regionally confined as well. Additionally, the available studies 
were also a mix of data from patients with uncomplicated and 
complicated cystitis. Further, much of the data about antimi-
crobial resistance has often have come from western countries. 
Unfortunately, this western data may not accurately reflect the 
drug resistance patterns in Asia because the patterns may be 
different among different countries (2, 5, 6). 
  In this study, we described the four key antimicrobials sus-
ceptibility patterns of the E. coli strains from AUC patients who 
were prospectively collected from 22 different medical centers 
in Korea. We also assessed the risk factors for antimicrobial-re-
sistant uropathogenic E. coli, and particularly their associations 
with fluoroquinolone resistance. 
MATERIALS AND METHODS
Patients and E. coli isolates 
All the female patients between 18 and 65 yr old and who pre-
sented with symptoms of dysuria, urgency, frequency or a com-
bination of these between May and October, 2006 were included 1206   http://jkms.org DOI: 10.3346/jkms.2010.25.8.1205
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in this study. The exclusion criteria were symptoms of or pre-
disposing factors for complicated cystitis. The women who had 
received antimicrobial agents in the 4 weeks previous to the 
study and those who were hospitalized were also excluded. A 
clean-catch midstream urine sample was tested by microscopy 
for the presence of leukocytes, and then it was sent to a central 
laboratory for culture and sensitivity testing. Only one specimen 
per patient was examined. No mixed infections were included. 
The E. coli included in the study were from cultures yielding ≥10
3 
colony forming units/mL and the urine displayed pyuria (2). 
  In total, 225 E. coli isolates were prospectively and consecu-
tively collected from the urine samples of the female outpatients 
with uncomplicated cystitis in 22 hospitals of Korea. In Seoul, 
62 samples were collected from 9 hospitals. In Gyeonggi-do, 
102 samples were collected from 4 hospitals. In Chungcheong-
do and Jeolla-do, 31 samples were collected from 5 hospitals. In 
Gyeongsang-do, 30 samples were collected from 4 hospitals. 
  The minimum inhibitory concentration (MIC) of ciprofloxa-
cin resistance was determined by the agar dilution method on 
Mueller-Hinton agar (Becton Dickinson and Company, Frank-
lin Lakes, NJ, USA), as recommended by the NCCLS (3). The 
number of cystitis episodes was classified into none, one and 
two recurrences in the previous year (2). 
  For easily handling of the data, we placed the intermediate 
resistant E. coli isolates into the resistant categories of each an-
timicrobial. This study was approved by the institutional review 
board of the Dankook University Medical Center (approval num-
ber: 0911-078). 
Statistical analysis 
Statistical analysis was performed by using Fisher’s exact test, 
chi-square tests, Student’s t-tests and the Mann-Whitney test. 
Multiple variables were assessed as predictors of the categorical 
outcomes by multivariable logistic regression analysis. P values 
≤0.05 were considered statistically significant. 
RESULTS
Determination of antimicrobials resistance was possible for 
more than 96.9% of the isolates (220 isolates to ampicillin, 221 
to co-trimoxazole and ciprofloxacin and 218 to cefazolin of the 
total 225 isolates). The E. coli isolates more commonly exhibit-
ed resistance to ampicillin (66.3%) and co-trimoxazole (31.2%), 
followed by ciprofloxacin (26.7%) and cefazolin (7.3%). 
  The association studies of the risk factors for antimicrobials 
resistance are shown in Table 1. The mean ages of the patients 
with sensitive and resistant isolates to ampicillin were 45.06± 
12.41 and 46.54±12.41 yr, respectively (P=0.40), those for co-tri-
moxazole were 45.30±12.38 and 47.37±12.66 yr (P=0.251), those 
for ciprofloxacin were 45.47±12.70 and 47.03±11.94 yr (P=0.42) 
and those for cefazolin were 45.85±12.42 and 48.87±13.14 yr 
(P=0.353), respectively. In the women aged older than 50 yr, the 
resistance rates to the four antimicrobials were not increased as 
compared to the women below that age (Table 1). 
  Some regional differences in ciprofloxacin resistance were 
shown. Of the E. coli isolates from Gyeongsang-do, 38.7% were 
ciprofloxacin resistant strains, whereas 20.6% of the E. coli iso-
lates from Gyeonggi-do were ciprofloxacin resistant strains (OR: 
2.43, 95% CI: 1.02-5.8, P=0.04). However, there were no signifi-
cant differences in ciprofloxacin resistance among Seoul and 
the Chungcheong-do & Jeolla-do and Gyeongsang-do. In addi-
tion, there were no statistical differences in co-trimoxazole, 
ampicillin and cefazolin resistance among the four regions. In-
terestingly, two recurrences of ACU in prior year was associated 
with ciprofloxacin (OR: 4.44, 95% CI: 1.34-14.74, P=0.01) and 
cefazolin resistance (OR: 5.33, 95% CI: 1.24-22.84, P=0.02). One 
recurrence in previous year was not related with the antimicro-
bials resistance. 
  We analyzed trends for the risk of resistance to the four anti-
microbials by performing multivariate analysis (Table 2). Resis-
tance to the four antimicrobials did not vary greatly according 
to age group. However, the samples from the south-west (Chun-
Table 1. Univariate analysis of risk factors for E. coli resistance to ciprofloxacin, co-trimoxazole, ampicillin and cefazolin 
Risk factors
Ciprofloxacin Co-trimoxazole Ampicillin Cefazolin 
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
Age (yr)
   <50
   ≥50
1
1.37 (0.75-2.48) 0.30
1
1.35 (0.76-2.39) 0.30
1
1.14 (0.65-1.99) 0.65
1
1.34 (0.48-3.71) 0.57  
Location 
   Gyeonggi-do
   Seoul
   Chungcheong & Jeolla-do
   Gyeongsang-do
1
1.34 (0.63-2.82)
2.23 (0.92-5.4)
2.43 (1.02-5.8)
0.43
0.075
0.04
1
1.49 (0.75-2.98)
1.46 (0.6-3.52)
1.84 (0.79-4.31)
0.25
0.39
0.15
1
1.20 (0.62-2.33)
2.00 (0.79-5.18)
1.44 (0.6-3.47)
0.57
0.13     
0.41      
1
1.20 (0.36-3.95)
0.48 (0.05-4.06)
1.43 (0.34-5.93)
0.76
0.50
0.61
Numbers of recurrence
   No
   One
   Two
1
1.27 (0.59-2.70)
4.44 (1.34-14.74)
0.538
0.01
1
0.77 (0.36-1.64)
1.08 (0.313-3.75)
0.50
0.09
1
1.36 (0.65-2.86)
1.09 (0.31-3.77)
0.41
0.89
1
1.30 (0.34-4.95)
5.33 (1.24-22.84)
0.70 
0.02
OR, odds ratio. http://jkms.org   1207 DOI: 10.3346/jkms.2010.25.8.1205
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gcheong-do & Jeolla-do; OR: 3.04, 95% CI: 1.19-7.80, P=0.02), 
and from the south-east (Gyeongsang-do; OR: 3.04, 95% CI: 1.22-
7.58, P=0.017) showed a risk for ciprofloxacin resistance when 
compared with the samples from the north (Gyeonggi-do), 
whereas the other antimicrobials did not reveal differences ac-
cording to the different region. In addition, the patients with 
ciprofloxacin or cefazolin resistant E. coli isolates were signifi-
cantly more likely to have histories of cystitis (two recurrences 
with ciprofloxacin resistant E. coli; OR: 6.71, 95% CI: 1.86-24.11, 
P=0.004 and two recurrences with cefazolin resistant E. coli; OR: 
5.72, 95% CI: 1.20-27.25, P=0.028) in previous year as compared 
with the non-recurrent patients. 
  Resistance to one antimicrobial was usually associated with 
resistance to another antimicrobial (Table 3). For example, the 
E. coli strains with ciprofloxacin resistance were significantly 
associated with resistance to ampicillin (P<0.001), co-trimoxa-
zole (P<0.001) and cefazolin (P=0.002).
DISCUSSION
The Korean Association of Urogenital Tract Infection and Inflam-
mation (KAUTII) reported previously that the resistance rates 
of E. coli from AUC patients to ciprofloxacin, cefazolin, ampicil-
lin and co-trimoxazole were 23.4%, 7.6%, 64.8 and 29.4%, respec-
tively (2). They also reported that Gyeongsang-do showed a trend 
for a higher rate of resistance to ciprofloxacin as compared with 
other regions (2). We have recently re-evaluated the raw data 
and re-analyzed the data together with the patient characteris-
tics to investigate the overall patterns and risk factors for resis-
tance to ciprofloxacin, cefazolin, ampicillin and co-trimoxazole 
in the E. coli isolates from patients with AUC. 
  Interestingly, resistance to ampicillin, co-trimoxazole, cefazo-
lin and ciprofloxacin did not significantly vary according to age 
group. However, it is a general rule that older aged patients are 
significantly associated with antimicrobial resistance. Moreover, 
some studies have also reported that older women with AUC 
show a higher chance for ciprofloxacin resistant E. coli than do 
the younger women (4, 6, 7). However, the four key antimicrobi-
als did not show any differences in their resistance by age group 
in our study. There are some possible reasons for this difference 
between our study and our studies. First of all, we applied very 
strict criteria for selecting AUC patients. The exclusion criteria 
were patients with symptoms of or predisposing factors for com-
plicated urinary tract infections, such as pregnancy, antimicro-
bial treatment within 2 weeks, symptoms lasting longer than 7 
days, fever, known urological or nephrological problems and 
more than 3 recurrences in previous year (2). In addition, all 
the female patients in our study were between 18 and 65 yr old 
Table 2. Multivariate analysis of risk factors for E. coli resistance to ciprofloxacin, co-trimoxazole, ampicillin and cefazolin 
Risk factors
Ciprofloxacin Co-trimmoxazole Ampicillin Cefazolin 
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value 
Age (yr)
   <50
   ≥50
1
1.24 (0.67-2.31) 0.49
1
1.31 (0.73-2.34) 0.37
1
1.08 (0.61-1.91 0.80
1
1.22 (0.43-3.51) 0.70  
Location
   Gyeonggi-do
   Seoul
   Chungcheong & Jeolla-do
   Gyeongsang-do
1
1.64 (0.74-3.63)
3.04 (1.19-7.80)
3.04 (1.22-7.58)
0.22
0.02
0.017
1
1.46 (0.72-2.96)
1.41 (0.57-3.48)
1.83 (0.77-4.32)
0.30
0.46
0.17
1
1.24 (0.63-2.44)
2.21 (0.85-5.74)
1.50 (0.62-3.64)
0.54
0.10
0.37
1
1.51 (0.42-5.45)
0.67 (0.07-6.14)
1.77 (0.40-7.80)
0.53
0.72
0.45
Numbers of recurrence
   No
   On
   Two
1
1.50 (0.68-3.30)
6.71 (1.86-24.11)
0.31
0.004
1
0.79 (0.37-1.73)
1.26 (0.35-4.55)
0.56
0.73
1
1.50 (0.7-3.18)
1.30 (0.37-4.66)
0.29
0.68
1
1.23 (0.32-4.82)
5.72 (1.20-27.25)
0.76 
0.028
OR, odds ratio. 
Table 3. Correlations in resistance among the four antimicrobials
Antimicrobials
Cefazolin Co-trimoxazole Ciprofloxacin Ampicillin
S (n) R (n) S (n) R (n) S (n) R (n) S (n) R (n)
Cefazolin
   S (n)
   R (n)
146
    8
60+
8
157
    6
49++
       10
75
  0
130++
       16
Co-trimoxazole 
   S (n)
   R (n)
132
  33
24+++
     36
72
  4
83+++
     65
Ciprofloxacin
   S (n)
   R (n)
73
  3
91+++
     57 
S, sensitive; R, resistant; n, number; +, P=0.095; ++, P=0.002; +++, P<0.001.1208   http://jkms.org DOI: 10.3346/jkms.2010.25.8.1205
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(mean±SD: 45.93±12.47 yr). The patients whose ages were over 
66 were not included because of the risk of complicated cystitis. 
We also dichotomized patient age into 18-49 yr olds and 50-65 
yr old, and re-analyzed the data. Clearly, the patient ages were 
not different in the dichotomized study. 
  The antimicrobial resistance was evaluated according to four 
geographic regions in Korea. Seoul is a big metropolitan city. 
Gyeonggi-do is also an urban area that surrounds Seoul. Chun-
gcheong and Jeolla-do is in the south-west and Gyeongsang-do 
is in the south-east. Near all the hospitals included in this study 
are tertiary university hospitals, and the estimated populations 
around the hospitals are above a half million. There was no dif-
ference in the age factor among the four provinces. In addition, 
there was no statistical difference in ciprofloxacin resistance 
among 4 hospitals in Gyeonggi-do (P=0.2). Gyeongsang-do, 
Chungcheong-do and Jeolla-do revealed a significantly higher 
rate of ciprofloxacin resistance when compared with that of 
Gyeonggi-do (Table 2). Although previous use of antimicrobials 
may be involved in the regional differences of antimicrobial re-
sistance, we must consider other factors such as the patients’ 
characteristics or sampling bias and the social and geological 
factors that have not yet been defined. 
  A history of AUC in the previous 1 yr was the other indepen-
dent variable for ciprofloxacin or cefazolin resistance. For the 
case of ciprofloxacin resistance, the results of our study were not 
surprising because fluoroquinolones has been prescribed em-
pirically and habitually in this region over the past decade. In 
addition, an association between the increase in fluoroquino-
lones prescriptions and an increase in its resistance has been 
reported in several countries (8, 10, 11).  
  The risk of cefazolin resistance was also increased in E. coli 
isolates from patients with two bouts of recurrent AUC in past 
year. Although all the previous prescriptions for the patients were 
not analyzed, the first generation cephalosporins have rarely 
been used to empirically treat AUC in Korea. Moreover, a small 
decrease in cefazolin resistance was recognized in 2006 (7.6%) 
when compared with the same study in 2002 by KAUTII (7.8%) 
(2, 3). If previous exposure to cefazolin was an important factor 
for resistance in our study, it is reasonable to consider that the 
prevalence of cefazolin resistance will increase year by year. 
  The risk of cephalosporin resistance in the E. coli isolates from 
AUC patients has not been well documented around the world. 
However, to the best of our knowledge, many doctors may con-
sider that the risk of cephalosporin resistance in the E. coli iso-
lates from AUC patients is not high. The finding that the E. coli 
isolates from patients with recurrent AUC have a trend for cefazo-
lin resistance is clinically very important because cephalospo-
rins are considered as an empirical treatment for urinary tract 
infections in countries with a high prevalence of fluoroquino-
lones resistance. 
  E. coli strains with ciprofloxacin resistance were also signifi-
cantly associated with resistance to ampicillin, co-trimoxazole, 
and cefazolin in our study. 
  Quinolone resistance is often associated with cross-resistance 
to many other structurally unrelated antimicrobials such as be-
ta-lactams, puromycin, tetracyclines, nalidixic acid and chlor-
amphenicol (12, 14). Its mechanism of the cross-resistance has 
not been clearly understood. Combinations of mutation in the 
topoisomerase-encoding genes, altered permeability and active 
efflux have been suggested as mechanisms. Altered permeabil-
ity and active efflux would also contribute to the decreased sus-
ceptibility to beta-lactams (15). 
  Fluoroquinolones have a broad spectrum antibiotic for Gram 
positive and Gram negative bacteria. They are also convenient 
for oral intake and have few side effects. With these advantages, 
the empirical treatment with fluoroquinolones has been a stan-
dard treatment for urinary tract infections in Korea. Concurrent-
ly and perhaps consequently, urinary tract infections due to flu-
oroquinolones-resistant E. coli strains have continued to increase 
at an alarming rate. However, there are very few choices to re-
place fluoroquinolone for empirical AUC treatment. Clearly, we 
should make a plan to reduce the antimicrobials resistance and 
be more cautious in using antimicrobials for AUC treatment in 
Korea, especially fluoroquinolone. Therefore, urine culture and 
antimicrobial susceptibility testing should be considered for 
the Korean AUC patients who have risk factors for antimicrobial 
resistance. 
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